MiNK Therapeutics (NASDAQ:INKT) Upgraded at Zacks Research

MiNK Therapeutics (NASDAQ:INKT) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research analysts also recently commented on INKT. Weiss Ratings raised MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a report on Monday, May 18th. Finally, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $35.00.

MiNK Therapeutics Stock Performance

Shares of MiNK Therapeutics stock opened at $11.09 on Tuesday. MiNK Therapeutics has a 1 year low of $8.48 and a 1 year high of $30.64. The firm’s 50-day simple moving average is $11.50 and its 200-day simple moving average is $11.39. The firm has a market cap of $55.25 million, a PE ratio of -3.90 and a beta of 0.47.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. On average, equities analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current year.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC raised its stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the period. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. 2.87% of the stock is owned by institutional investors and hedge funds.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.